|
Título:
|
Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis
|
|
Autores:
|
Peloquin, Charles A. ;
Phillips, Patrick P. J. ;
Mitnick, Carole D. ;
Eisenach, Kathleen ;
Patientia, Ramonde F. ;
Lecca, Leonid ;
Gotuzzo, Eduardo ;
Gandhi, Neel R. ;
Butler, Donna ;
Diacon, Andreas H. ;
Martel, Bruno ;
Santillan, Juan ;
Hunt, Kathleen Robergeau ;
Vargas, Dante ;
von Groote-Bidlingmaier, Florian ;
Seas, Carlos ;
Dianis, Nancy ;
Moreno-Martinez, Antonio ;
Kaur, Pawandeep ;
Horsburgh, C. Robert
|
|
Tipo de documento:
|
texto impreso
|
|
Editorial:
|
American Society of Microbiology, 2018-11-30T17:17:13Z
|
|
Nota general:
|
info:eu-repo/semantics/restrictedAccess
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
|
|
Idiomas:
|
Inglés
|
|
Palabras clave:
|
Editados por otras instituciones
,
Artículos
,
Artículos en revistas indizadas
|
|
Resumen:
|
Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other second-line agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 ?g · h/ml. Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 ?g/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. (This study has been registered at ClinicalTrials.gov under identifier NCT01918397.).
|
|
En línea:
|
https://doi.org/10.1128/aac.00770-18
|
